Table 1 Relationship between HOXB9 expression and clinicopathological features in endometrial carcinomas
From: HOXB9 promotes endometrial cancer progression by targeting E2F3
HOXB9 | ||||
|---|---|---|---|---|
Features | Case (N) | Low N (%) | High N (%) | P-value |
Age | 0.2396 | |||
≤50 | 41 | 19 (46) | 22 (54) | |
>50 | 47 | 16 (34) | 31 (66) | |
Surgical staging | 0.1041 | |||
I | 53 | 19 (36) | 34 (64) | |
II | 18 | 11 (61) | 7 (39) | |
III–IV | 17 | 5 (29) | 12 (71) | |
Histological grade | 0.0081 | |||
G1 | 29 | 18 (62) | 11 (38) | |
G2 | 26 | 9 (35) | 17 (65) | |
G3 | 33 | 8 (24) | 25 (76) | |
Muscular invasion endomembrane | 0.2446 | |||
≤1/2 | 39 | 12 (31) | 27 (69) | |
>1/2 | 49 | 21 (43) | 28 (57) | |
Lymph node metastisis | 0.001 | |||
Yes | 39 | 8 (21) | 31 (79) | |
No | 49 | 27 (55) | 22 (45) | |
